mirabegron
CHEBI:CHEBI_65349
Definition
A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2-amino-1,3-thiazol-4-ylacetic acid with the anilino group of (1R)-2-{[2-(4-aminophenyl)ethyl]amino}-1-phenylethanol. Used for the treatment of overactive bladder syndrome.
Chemical Information
- Molecular Formula
- C21H24N4O2S
- Molecular Mass
- 396.50600
- Charge
- 0
- SMILES
- Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1
- InChI
- InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1
- InChIKey
- PBAPPPCECJKMCM-IBGZPJMESA-N
Alternative Names
- 2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide
- mirabegron
- Myrbetriq
Drug Classification
-
1,3-thiazolesView Class →
CHEBI:38418
-
monocarboxylic acid amideView Class →
CHEBI:29347
-
aromatic amideView Class →
CHEBI:62733
-
ethanolaminesView Class →
CHEBI:23981
-
t269633
Important Medical Information
⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.
- Always consult with a healthcare professional before starting, stopping, or modifying any medication.
- Side effects may vary and this list may not be comprehensive.
- Drug interactions may occur with other medications.
Additional Identifiers
- DRON_00010000
- 1300786
- oboInOwl#hasDbXref
- Reaxys:11023250
- core#notation
- CHEBI:65349
Additional References
🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.
Additional Attributes
- manufacturer_name
- REMEDYREPACK INC.
- package_marketing_start_date
- 08-JUN-16
- package_description
- 25 kg in 1 CARTON (64552-4077-1)
- package_ndc
- 65085-0067-9
- listing_expiration_date
- 20241231
- route
- ORAL
- marketing_start_date
- 20160608
- spl_id
- 35b515f1-01cf-4fd0-a7c6-e632669c1277
- labeler_name
- Amoli Organics (A Division of Umedica Laboratories Pvt.Ltd.)
- oboInOwl#hasOBONamespace
- chebi_ontology
- DRON_00010000
- 1300786
- oboInOwl#hasDbXref
- Reaxys:11023250
- oboInOwl#id
- CHEBI:65349
- generic_name
- Mirabegron (Alpha-Form)
- brand_name
- Mirabegron
- brand_name_base
- Mirabegron
- product_type
- BULK INGREDIENT
- marketing_category
- BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
- dosage_form
- GRANULE, FOR SUSPENSION, EXTENDED RELEASE
- product_ndc
- 64552-4077
- application_number
- ANDA209485
- oboInOwl#inSubset
- http://purl.obolibrary.org/obo/chebi#3_STAR
- RO_0000087
- http://purl.obolibrary.org/obo/CHEBI_35522
- core#notation
- CHEBI:65349
- rxcui
- 2541237
- active_ingredient_strength
- 50 kg/50kg
- pharm_class_moa
- Cytochrome P450 3A Inhibitors [MoA]
- pharm_class
- Cytochrome P450 3A Inhibitors [MoA]
- active_ingredient_name
- MIRABEGRON
- unii
- MVR3JL3B2V
- spl_set_id
- d22d3d12-8466-46db-bc19-d13e87c6115c
- nui
- N0000185503
- pharm_class_epc
- beta3-Adrenergic Agonist [EPC]
- upc
- 0368180152064
- 22-rdf-syntax-ns#type
- http://www.w3.org/2002/07/owl#Class
- has_treatment
- http://purl.obolibrary.org/obo/DOID_0070355
- rdf-schema#domain
- https://w3id.org/def/predibionto#has_side_effect31367
- owl#annotatedSource
- t269842
- owl#someValuesFrom
- t3776511